Edoc Acquisition Corp

Edoc Acquisition — SPAC Merger (May 2022)

31 slides from Edoc Acquisition's SPAC merger presentation, May 25, 2022

  1. Slide 1: Calidi: clinical-stage biopharmaceutical company with stem cell-based oncolytic viral platforms

    is a clinical - stage biopharmaceutical company revolutionizing oncolytic viral therapies with stem cell - based platforms May 2022

  2. Slide 2: Forward-looking statements

    This presentation contains forward - looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possib

  3. Slide 3: Important Information About the Business Combination Transaction and Where to Find It

    This presentation relates to a proposed business combination between Edoc Acquisition Corp. a Cayman Islands exempted company, EDOC Merger Sub Inc., a Nevada corporation and Calidi Biotherapeutics, Inc., a Nevada corporation . A full description of the terms and conditions Agreement and Plan of Merg

  4. Slide 4: Participants in solicitation; No offer or solicitation

    Edoc Acquisition Corp., Calidi Biotherapeutics, Inc., and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies or consents from Edoc Acquisition Corp. and Calidi Biotherapeutics, Inc. shareholders in connection with the proposed transactio

  5. Slide 5: Calidi Financing

    Calidi Financing I. Historical II. Planned DeSPAC with EDOC Acquisition Corp: Anticipated in July – August 2022 III. Use of Proceeds: Funding for 3 years of operations and 3 clinical trials IV. Crossover Funding Page 5 © 2022 Calidi Biotherapeutics, Inc. І Company Proprietary; Patents issued and pen

  6. Slide 6: Company Highlights

    Company Highlights Two First - in - Class Novel Clinically Focused Platforms With Broad and Long - Lasting IP Protection NeuroNova ( NNV ): - Off - the - shelf Allogeneic neural stem cells (HB1.F3.CD21) loaded with oncolytic adenovirus (CRAD - s - pk7) to treat Glioblastoma (GBM) - Completed Phase 1

  7. Slide 7: Oncolytic Virus Platform: Calidi's Platform Advantages

    COMPANY Oncolytic Virus Platform Cell Protected : Vaccinia Virus Adenovirus Herpes Virus Herpes Virus Adenovirus Herpes Virus Adenovirus Vaccinia Virus Engineered Virus FDA Approved Virus Reduced viral elimination by the immune system Virally - encoded therapeutic expressed at administration Stem ce

  8. Slide 8: Current Obstacles to Oncolytic Virus Therapy

    Current Obstacles to Oncolytic Virus Therapy Problems with Oncolytic Viruses: The unprotected oncolytic viruses are quickly eliminated by the patient’s immune system This leads to a very limited therapeutic potential HUMAN CLINICAL SCENARIO when using naked virus ACTIVE ONCOLYTIC VIRUSES RAPID INACT

  9. Slide 9: Calidi's Solution: Stem Cell-Based Platforms to Potentiate Oncolytic Viral Therapies

    CALIDI’S SOLUTION: Stem Cell - Based Platforms to Potentiate Oncolytic Viral Therapies Stem cells loaded with oncolytic viruses are manufactured in a single off - the - shelf vial 1. Stem cell loaded with Oncolytic Viruses (OV) 2. Stem cell protects and amplifies OV 3. Protected viruses delivered to

  10. Slide 10: Preclinical in vitro data shows Vaccinia Virus kills tumor cells

    Preclinical in vitro data shows that Vaccinia Virus (VACV) kills tumor cells PC3 (prostate cancer) + HUMAN SERUM Vaccinia virus (VACV) engineered to express red fluorescent protein. RED signal indicates virus amplification leading to killing of cancer cells Treatment: CAL1 – naked virus Treatment: C

  11. Slide 11: Differentiated Pipeline Targeting Multiple Cancer Indications

    Differentiated Pipeline Targeting Multiple Cancer Indications * Calidi has observed data related to a physician sponsored 26 - patient safety trial (IRB) with autologous adipose - derived stromal cells delivering CAL1 oncolytic virus NeuroNova SuperNova Program Description Target Indications Discove

  12. Slide 12: NeuroNova Platform

    © 2022 Calidi Biotherapeutics Ρ | Proprietary & Confidential, Patents issued and pending NeuroNova Platform 12

  13. Slide 13: NeuroNova Platform Overview

    NeuroNova Platform Overview Image Source: Lancet Oncology Journal (June 29 th , 2021) » Possess inherent ability to distribute throughout tumor mass as well as migrate to distant tumor sites regardless of tumor size, anatomic location, or tissue type » Calidi’s platform, NeuroNova1 (NNV1), is compri

  14. Slide 14: NNV1 Phase 1 Trial Design in Newly Diagnosed Malignant Glioma

    Neural Stem Cell Delivery of an Oncolytic Adenovirus in Newly Diagnosed Patients with Malignant Glioma: A First - in - Human, Phase 1 Clinical Trial (Lancet Oncology, 2021 Aug;22(8):1103 - 1114) NNV1 (NSC.CRAd - S - pk7) Phase 1 Trial Design Agent: NSC - CRAd - S - pk7: Neural stem cells loaded with

  15. Slide 15: NNV1 Clinical Trial Results

    NNV1 Clinical Trial Results Treatment with NNV1 (NSC - CRAd - S - pk7) was safe and tolerable Treatment achieved favorable therapeutic outcomes in patients with newly diagnosed malignant glioma: best overall response saw one patient responding partially to treatment, another progressing, and 10 with

  16. Slide 16: SuperNova Platform

    © 2022 Calidi Biotherapeutics Ρ | Proprietary & Confidential, Patents issued and pending SuperNova Platform 16

  17. Slide 17: SuperNova Platform Overview

    SuperNova Platform Overview » AD - MSC have significant advantages over other MSCs because of their ease of extraction, maintained potency with age of the donor, significant anti - inflammatory & immune - suppressive properties and documented tumor homing ability » Calidi’s product candidate, SuperN

  18. Slide 18: Autologous adipose derived stromal cells loaded with CAL1: Phase 1 Trial

    Autologous adipose derived stromal cells loaded with oncolytic vaccinia virus CAL1: Phase 1 Trial Design Agent: SNV0: Adipose - derived autologous cells loaded with CAL1 – a non - modified oncolytic vaccinia virus Study design: Open - label, phase 1, dose - escalation clinical trial in patients with

  19. Slide 19: Patient Case: Thyroid Papillary Carcinoma

    SI - 001 Patient Case: Patient #SI01 - 047 • Age/Sex: 68/M • Diagnosis: Thyroid Papillary Carcinoma • Stage IV • Treatment Date / Location: 7/19/17 BH • Treatment Details: IT in right lesion 37x10 6 SC in 0.75ml - (3.75x10 6 pfu) IT in left lesion 12x10 6 SC in 0.25ml - (1.25x10 6 pfu) Day 85 post -

  20. Slide 20: Patient Case: Metastatic Head & Neck SCC

    SI - 001 Patient Case: Patient #SI01 - 021 • Age/Sex: 70/M • Diagnosis: Metastatic Head & Neck SCC • Stage IV_B • Injected tumor was resistant to chemo - and radio - therapy • Treatment Date / Location: 12/17/2015 / BH • Treatment Details: IV 19.7x10 6 SC in 0.6ml - (1.9x10 6 PFU) IT 3.3x10 6 SC in

  21. Slide 21: Clinical Observations and Development Pathway

    Clinical Observations and Development Pathway Autologous adipose derived stromal cells delivering CAL1 oncolytic virus - Clinical Observations Combined application of stem cells and vaccina virus was well tolerated in all patients Results of the plasma cytokine assays suggested inflammatory reaction

  22. Slide 22: Experienced Team with Proven Track Record

    Experienced Team with Proven Track Record ALLAN CAMAISA Chairman & CEO GEORGE NG President & Chief Operations Officer STEPHEN THESING Chief Business Officer BORIS MINEV, M.D. President, Medical & Scientific Affairs, Acting CMO WENDY PIZARRO, ESQ. Chief Admin Officer & Chief Legal Officer ANTONIO F.

  23. Slide 23: Company Highlights

    Company Highlights Two First - in - Class Novel Clinically Focused Platforms With Broad and Long - Lasting IP Protection NeuroNova ( NNV ): - Off - the - shelf Allogeneic neural stem cells (HB1.F3.CD21) loaded with oncolytic adenovirus (CRAD - s - pk7) to treat Glioblastoma (GBM) - Completed Phase 1

  24. Slide 24: Contacts

    Contacts Stephen Thesing – Chief Business Officer & Investor Relations sthesing@calidibio.com 1.858.386.3776 George Ng – President and COO gng@calidibio.com 1.858.705.8594 Page 24 © 2022 Calidi Biotherapeutics, Inc. І Company Proprietary; Patents issued and pending

  25. Slide 25: Appendix

    © 2022 Calidi Biotherapeutics Ρ | Proprietary & Confidential, Patents issued and pending Appendix 25

  26. Slide 26: Broad IP Protection Across All Clinical Programs in Development

    Broad IP Protection Across All Clinical Programs in Development Allogeneic Adipose Tissue - derived and Neural Stem Cell Platforms for Delivery of Oncolytic Viruses Tropic Cell - Based Virotherapy for the Treatment of Cancer Smallpox Vaccine for Treatment of Cancer Combination Immunotherapy Approach

  27. Slide 27: Recent Calidi Developments

    Recent Calidi Developments February 2nd, 2022 : Calidi announces merger with EDOC Acquisition Corp February 7 th , 2022 : Alfonso Zulueta , former President at Eli Lilly International joins Calidi Board of Directors March 16 th , 2022 : Calidi/EDOC files S - 4 to the SEC DeSPAC : Anticipated July -

  28. Slide 28: Board of Directors

    Board of Directors Allan Camaisa Chairman & CEO . Led $ 20 M early - stage Series A round and oversaw collaboration agreement with National Institutes of Health . Led key account engagements, including Roche, Johnson & Johnson, the US Veterans Administration, and CMS . Ernst and Young Entrepreneur o

  29. Slide 29: Principal Investigators and KOLs

    Principal Investigators and KOL’s Roger Stupp, M.D. » Professor, Division Chief, Neuro - Oncology , Northwestern University » Internationally recognized medical oncologist, expert on GBM treatment » Established the “ stupp protocol” for temozolomide (Temodar®) and radiation in the first line treatme

  30. Slide 30: Principal Investigators and KOLs

    Principal Investigators and KOL’s Santosh Kesari, M.D. » Director of Neuro - oncology and chair of the Department of Translational Neurosciences and Neurotherapeutics at John Wayne Cancer Institute at Providence Saint John’s Health Center » Focused on personalized medicine for patients with malignan

  31. Slide 31: Benefits of Using Allogeneic Stem Cells to Manufacture Calidi's Products

    Benefits of Using Allogeneic Stem Cells to Manufacture Calidi’s Products Scale and Patient Compliance : Billions of doses can be manufactured from a single mini liposuction of a healthy donor. These allogeneic products have a long shelf life and can be shipped frozen to any clinic and used immediate

Edoc Acquisition — SPAC Merger (May 2022) on 6ix